Purpose: To evaluate efficacy and survival rates of intraocular pressure (IOP)-lowering effect obtained with phacoemulsification (phaco) alone or in combination with canaloplasty (PCP) in patients with open-angle glaucoma (OAG).
N umerous studies demonstrate that phacoemulsification (phaco) may produce long-term reduction of intraocular pressure (IOP) in subjects without glaucoma, 1, 2 patients with pseudoexfoliation syndrome, 3, 4 or glaucoma patients. [5] [6] [7] [8] The effect is thought to be mediated by 3 major mechanisms: hyposecretion of aqueous humor due to production of free radicals or partial ciliary body detachment and irritation; improved uveo-scleral outflow due to increased synthesis of endogenous prostaglandins; and improved trabecular outflow due to increased space in the anterior chamber resulting in increased posterior traction on the scleral spur and expansion of the trabecular meshwork and Schlemm canal (SC), and washing out effect on trabecular meshwork. [8] [9] [10] Canaloplasty is a new surgical technique that provides an alternative to trabeculectomy. 11 The procedure combines nonpenetrating deep sclerotomy with a modified viscocanalostomy utilizing a microcatheter (iTrack & iLumen; iScience International, Menlo Park, CA). Transtrabecular flow is also thought to be enhanced by distending SC 360 degrees with a 10-0 or 9-0 prolene suture. The procedure greatly reduces the likelihood of bleb formation; therefore, the number of postoperative visits may be reduced. Furthermore, there is less long-term risk of bleb-related endophthalmitis associated with canaloplasty.
Although there is a body of literature addressing the efficacy and safety of canaloplasty, [11] [12] [13] [14] [15] [16] the data on canaloplasty in combination with phacoemulsification are limited. 15, 17 The goal of this study was to evaluate efficacy, safety, and success rates of the IOP-lowering effect obtained with phaco alone or in combination with canaloplasty (PCP) in patients with open-angle glaucoma (OAG).
METHODS
We performed a retrospective chart review of consecutive phacoemulsification procedures from April 30, 2007 to April 15, 2010 Visual acuity (VA), IOP, number of medications, success and survival rate of IOP-lowering effect, incidence of complications, and further surgical interventions were analyzed. We used the Tube Versus Trabeculectomy study failure criteria 18 : IOP >21 mm Hg or <20% reduction below baseline on 2 consecutive follow-up visits after 3 months, IOP <6 mm Hg on 2 consecutive follow-up visits after 3 months, further glaucoma surgery, or loss of light perception vision. Eyes that did not fail and did not require supplemental glaucoma medications were classified as complete successes. Eyes that did not fail but required supplemental glaucoma medications were classified as qualified successes.
Surgical Procedures
Phaco with temporal clear corneal incision and posterior chamber intraocular lens implant were performed on all patients. The canaloplasty technique was described previously. 13 In the PCP procedure, initially a conjunctival peritomy was performed 10 mm superior to the limbus and conjunctiva, and Tenon capsule were dissected toward the limbus. Superficial and deep scleral flaps were dissected as previously described. The phaco procedure was performed through clear cornea. The deep scleral flap was then elevated to unroof SC and expose a trabeculo-Descemet membrane. A flexible microcatheter (iTrack-250A; iScience Interventional, Menlo Park, CA) was advanced into the SC 360 degrees. A red-blinking light at the distal tip of the catheter helped ensure the proper location of the catheter. After complete catheterization of the SC, a 10-0 or 9-0 polypropylene suture was tied to the exposed distal tip of the catheter at the surgical cut-down and looped through the SC. At the same time, Healon GV (AMO, Abbott Park, IL) was injected to dilate the SC while the catheter was withdrawn. The suture was cut from the catheter and tied under tension to dilate the SC. The deep scleral flap was excised, and superficial flap was repositioned and secured to the sclera with one 9-0 nylon suture. The conjunctiva and Tenon capsule were closed with running 8-0 vicryl suture.
The Fisher exact test was used for categorical data analysis. The Student t test was used for continuous parametric data (IOP, follow-up time) and the Mann-Whitney U test was used for nonparametric data (log MAR , number of medications). Survival rates were analyzed using the KaplanMeier life-table analysis and the log rank test. P-values <0.05 were considered statistically significant.
RESULTS
One eligible eye from each subject was included in the study. If both eyes were qualified for the study, an eye that underwent surgical procedure first was included in the study. Thirty-seven patients underwent phaco alone and 32 patients had PCP procedure. None of the canaloplasty cases were excluded from the analysis. Thirty-five phaco cases were excluded due to diagnosis of chronic angle-closure glaucoma.
Follow-up was 21. 8 ± 10.1 versus 18.8 ± 9.6 months for phaco and PCP, respectively (P = 0.21). Age, laser status, central corneal thickness, mean deviation, and pattern standard deviation were similar in both groups. Majority of patients were whites and had primary OAG (Table 1 ). There were no statistically significant differences in preoperative VA (Table 2) , IOP (Table 3) , or number of glaucoma medications (Table 4) .
When analyzing each study group separately, we found that postoperative VA (Table 2 ) and IOP (Table 3) were statistically different than preoperative VA and IOP (all P = 0.001). In the phaco group, the postoperative number of glaucoma medications was statistically lower than the preoperative number of glaucoma medications at 3 months (P = 0.001) and at 6 months (P = 0.001), but not at 12 months (P = 0.52), at 18 months (P = 0.48), or at 24 months (P = 0.33). In the PCP group, the postoperative number of medications was statistically lower than the preoperative number of medications at all postoperative periods of time (all P = 0.001) ( Table 4) .
When comparing 2 study groups, we did not find a statistically significant difference in postoperative VA between 2 study groups ( Table 2) . Compared with the phaco group, the PCP group had statistically significantly lower IOP at 3 and 12 months postoperatively but not at 6, 18, or 24 months (Table 3) . Compared with the phaco group, the PCP group had statistically significantly lower number of medications at all postoperative points in time (Table 4) . Intraoperative complications included 1 posterior capsule rupture and 1 Descemet membrane rupture in the PCP group. On the first day after the surgery, both groups had similar number of IOP spikes and iris incarceration (1 in each group). Both iridi were incarcerated into paracentesis wound and were managed in the office with wound burping, viscoelastic, and pilocarpine 2% eye drops. In addition, the PCP group had cases of hyphema (n = 8), hypotony (n = 7), and bleb formation (n = 8) detected during the first postoperative day. Early (onset <3 mo) postoperative period was notable for the development of IOPZ30 mm Hg in 1 eye and choroidal detachment in 1 eye in the PCP group. No complications were detected in the subsequent (onset >3 mo) postoperative period in either study group. All complications are summarized in Table 5 .
For complete success (Fig. 1A) , survival for the PCP group was 0.75 at 12 months (n = 12 remaining cases), 0.63 at 18 months (n = 8 remaining cases), and 0.63 at 24 months (n = 6 remaining cases); survival for the phaco group was 0.34 at 12 months (n = 6 remaining cases), 0.28 at 18 months (n = 4 remaining cases), and 0.21 at 24 months (n = 0 remaining cases). The difference was statistically significant (P = 0.003, log rank test). For qualified success (Fig. 1B) , survival for the PCP group was 0.77 at 12 months (n = 14 remaining cases), 0.66 at 18 months (n = 10 remaining cases), 0.66 at 24 months (n = 8 remaining cases); survival for the phaco group was 0.49 at 12 months (n = 15 remaining cases), 0.45 at 18 months (n = 11 remaining cases), and 0.41 at 24 months (n = 4 remaining cases). The difference was statistically significant by the log rank test (P = 0.049) but not by the Breslow test (P = 0.056).
Failures in both groups occurred due to IOP > 21 mm Hg or r20% reduction below baseline on 2 consecutive follow-up visits after 3 months. In the canaloplasty group, 1 case was classified as failure due to postoperative IOP equaled preoperative IOP value, and 5 cases were classified as failures due to postoperative IOP reduction <20% from the preoperative value. In the phaco group, 10 cases were classified as failures due to increase in postoperative IOP compared with preoperative IOP (range, 5% to 64%); in 1 case, the postoperative IOP was equal to preoperative IOP; and 8 cases were classified as failures due to postoperative IOP reduction <20% from the preoperative value. There were no cases of further glaucoma reoperations.
DISCUSSION
Our study demonstrated that PCP had higher complete success rate and survival rates at 12, 18, and 24 months than phaco alone (Fig. 1) . Although the PCP group had lower VA than the phaco group, the differences were not statistically significant (all P > 0.05). One person in the PCP group had VA count fingers postoperatively due to development of wet age-related macular degeneration resulting in lower mean VA in the PCP group compared with the phaco group. Within each group, postoperative vision was significantly better than preoperative vision (all P < 0.01).
In our study, both phaco and PCP had IOP-lowering effect lasting up to 24 months postoperatively. Both hyphema and bleb formation that occurred postoperatively in the PCP group resolved spontaneously. In the phaco group, the number of postoperative medications approached the number of preoperative medications by 12 months postoperatively. However, the postoperative IOP remained significantly lower than preoperative IOP, confirming IOP-lowering effect of the phaco procedure. Most phaco cases were performed by the same surgeon who performed canaloplasty. The remaining number of phaco cases performed by the 2 other surgeons was not large enough to conduct a meaningful statistical analysis for each surgeon separately. In addition, there is little evidence to suggest significant variations in the IOP response to phaco by different surgeons and pooling of data is commonly reported in the literature. Although standard criteria for adding medications may have been helpful, criteria for adding back medications were left to the discretion of the surgeon. In majority of cases, glaucoma medications were added for postoperative IOP < 20% reduction. In contrast to the phaco group, the number of glaucoma medications was significantly reduced in the PCP group postoperatively and remained so at all postoperative points in time. The net effect was 1 less medication for the PCP group compared with the phaco-alone group. Furthermore, survival rates of complete success were statistically higher for PCP procedure than for phaco alone. As the study patients had medically controlled glaucoma, the main reason to perform a combined procedure was to lower the number of medications, which can have a significant impact on glaucoma management. Thus, this combined procedure could be potentially cost-saving, as majority of glaucoma patients are diagnosed at the earlier stage of the disease and are likely to be on eye drops for a prolonged period of time.
The phaco results of our study are in accord with the results from the studies conducted by other investigators. Pohjalainen et al 4 studied the effect of phaco on IOP in 38 eyes with OAG. In their study on average mean IOP decreased from 18.4 ± 3.3 mm Hg preoperatively to 15.1 ± 2.9 mm Hg 2.8 years postoperatively (P = 0.001). The average number of medications at the end of the study (n = 1.7) was similar to the preoperative values (n = 1.6). More recently, Poley et al 8 retrospectively evaluated longterm effects of phaco on IOP in nonglaucomatous and glaucomatous eyes. They found a mean IOP decrease of 2.7 mm Hg up to 10 years postoperatively in all eyes. However, in eyes with higher preoperative IOP (range, 23 to 29 mm Hg), postoperative mean IOP decrease was significantly larger (8 mm Hg). The authors concluded that phaco with intraocular lens should be considered a treatment option in eyes with glaucoma and high IOP.
Our PCP results were similar to the results from a prospective study conducted by Shingleton et al. 17 The authors evaluated data from 54 eyes that had PCP performed by 11 different surgeons at 9 international centers. In their study, the mean IOP decreased from 24.4 ± 6.1 mm Hg preoperatively to 13.7 ± 4.4 mm Hg at 12 months postoperatively. Medications usage decreased from 1.5 ± 1.0 preoperatively to 0.2 ± 0.4 at 12 months. Lewis et al 15 analyzed data from the same patient cohort at 3 years postoperatively. Both mean IOP and number of medications remained stable: 13.6 ± 3.6 and 0.3 ± 0.5 mm Hg, respectively.
Both phaco and PCP increase aqueous outflow by expanding the trabecular meshwork and SC. However, PCP, in addition to restoring trabecular-SC-collector channel outflow pathway, also increases aqueous outflow through nonpenetrating deep sclerotomy route. The greatest potential advantage of combining the 2 procedures is decreasing the number of medications required to maintain successful IOP lowering. Weaknesses of our study include retrospective analysis and selection bias. Despite of this being retrospective study with all eligible cases included, with about 35 subjects in each group, our study had 90% power to detect an increase from 0.35 survival rate at 1 year in the phaco group to 75% survival rate at 1 year in the PCP group. In the tables, we included successful eyes and eyes failed from low or high IOP. We felt that excluding those eyes would artificially increase effectiveness of phacoemulsification or PCP procedures. In addition, because of retrospective nature of our study, we rounded some of the follow-up periods to the nearest time point ± 3 months. The strengths are 24-month follow-up and standardized failure criteria. It is reasonable to postulate that more cases in the phaco and PCP groups may fail with time, although perhaps not at the same rate. This is a retrospective study designed to present the intermediate follow-up and that although the plan is to report longer follow-up, longer-term retrospective studies often suffer from more loss of follow-up of individual patients. Nonetheless, our study provides further evidence that combining canaloplasty with phaco achieves IOP lowering with fewer medications compared with phaco alone. PCP would be especially valuable in patients with cataract and glaucomatous optic neuropathy that are at risk for further glaucomatous damage but do not yet require trabeculectomy.
In conclusion, our study demonstrates that PCP may be a reasonable additional procedure for a selective group FIGURE 1. Kaplan-Meier plots: A, Cumulative probability of complete (without glaucoma medications) success in the phaco and phaco-canaloplasty (PCP) study groups. B, Cumulative probability of qualified (glaucoma medications allowed) success in the phaco and PCP study groups.
of patients with OAG who undergo phaco surgery. A combination of canaloplasty with phaco results in a decreased number of glaucoma medications while increasing the complete success rate for IOP-lowering effect without medication compared with phaco alone. Prospective long-term randomized studies are needed to validate our findings.
